Sandoz, Mylan Slip Teva Patent Suits Over MS Drug Research

Law360, New York (July 16, 2013, 5:05 PM EDT) -- Mylan Pharmaceuticals Inc. and Sandoz Inc. on Tuesday escaped almost identical infringement suits by Teva Pharmaceuticals Ltd. after they agreed to stop using its patented technology in seeking U.S. Food and Drug Administration approval for generic versions of Teva's multiple sclerosis drug Copaxone.

U.S. District Katherine Forrest granted motions to dismiss by Mylan and Sandoz after they told her that they would no longer use certain polypeptide markers to measure the weight of samples of glatiramer acetate, the active ingredient in Copaxone. Teva’s suits accused them...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.